1 The pharmaceutical compound, dihydroergotamine (DHE) is dispensed to prevent and reduce the occurrence of migraine attacks. Although still controversial, the prophylactic effect of this drug is believed to be caused through blockade and/or activation of numerous receptors including serotonin (5-HT) receptors of the 5-HT 2 subtype. 2 To elucidate if 5-HT 2 receptors (5-HT 2 Rs) may be involved in DHE prophylactic effect, we performed investigations aimed to determine the respective pharmacological profile of DHE and of its major metabolite 8 0 -hydroxy-DHE (8 0 -OH-DHE) at the 5-HT 2B and 5-HT 2C Rs by binding, inositol triphosphate (IP 3 ) or cyclic GMP (cGMP) coupling studies in transfected fibroblasts. 3 DHE and 8 0 -OH-DHE are competitive compounds at 5-HT 2B and 5-HT 2C Rs. 8 0 -OH-DHE interaction at (5-HT 2B Rs) was best fitted by a biphasic competition curve and displayed the highest affinity with a K i of 5 nm. These two compounds acted as agonists for both receptors in respect to cGMP production with pEC 50 of 8.3270.09 for 8 0 -OH-DHE at 5-HT 2B and 7.8370.06 at 5-HT 2C Rs.
Introduction
Serotonin receptors are highly heterogeneous and they have been regrouped within different families (5-HT 1 -5-HT 7 ). With the exception of the 5-HT 3 receptors, which are ligand-gated ion channels, all others are G-protein-coupled receptors with each family sharing structural, pharmacological and transductional characteristics (Hoyer et al., 2002) . 5-HT receptors (5-HTRs) have been implicated in the regulation of several psychiatric and neurological disorders related to serotonergic neurotransmission, and specific receptor subtypes have recently been associated with either the pathogenesis or the treatment of migraine headache (Villalon et al., 1997) .
A role for 5-HT in migraine has been supported by sudden changes in circulating levels of 5-HT and its metabolites observed during the early phases of a migraine attack (Goadsby, 2000) , along with the ability of 5-HT-releasing agents to induce migraine-like symptoms (Kalkman, 1994; Panconesi & Sicuteri, 1997) . Migraine patients have a systemic disturbance of 5-HT metabolism, associated with low 5-HT plasma levels between attacks and increased levels and release of platelet 5-HT during attacks (Ferrari, 1998) . Contrary to earlier belief, the rise of plasma 5-HT is not the cause of migraine but probably represents a self-defence mechanism. Earlier observations showed that injection of 5-HT can abort migraine attacks, but at the cost of significant side effects. These findings led to the hypothesis that selective stimulation of 5-HTRs might safely abort attacks (Ferrari, 1998) . The development of 5-HTR agonists with efficacy in the clinic for the alleviation of migraine pain further implicates 5-HT as a key molecule in migraine (Goadsby et al., 2002) .
Several theories regarding the aetiology of migraine have been proposed (Ferrari, 1998; Johnson et al., 1998; Goadsby et al., 2002) . The vasodilatory theory of migraine suggested that extracranial arterial dilation during an attack was related to migraine pain; a theory supported when vasoconstrictors such as sumatriptan alleviated migraine pain. The neurological theory of migraine proposed that migraine resulted from abnormal firing in brain neurons. Cortical spreading depression, one facet of the neurological theory, could explain the prodrome of migraine. The neurogenic dural inflammation theory of migraine supposed that the dural membrane surrounding the brain became inflamed and hypersensitive due to release of neuropeptides from primary sensory nerve terminals. A role for 5-HT is supported by the efficacy in treating acute migraine pain and associated symptoms of 5-HTR ligands such as triptans, which are agonists at 5-HT 1D and 5-HT 1B R subtypes. In addition, the prophylactic effect of several pharmaceuticals frequently dispensed to prevent the occurrence of migraine attacks has been suggested to be caused through blockade of 5-HTRs of the 5-HT 2 type (Kalkman, 1994; Panconesi & Sicuteri, 1997) . Migraine headache is thought to be transmitted by the trigeminal nerve from the meninges and their blood vessels. Various human meningeal tissues express 5-HT 1B/1D , 5-HT 2A , 5-HT 2B , 5-HT 4 and 5-HT 7 R mRNAs (Schmuck et al., 1996) . 5-HT 2C R mRNA was found in neurons involved in the central processing of nociceptive neurotransmission (Molineaux et al., 1989) .
The ergot alkaloids and their semisynthetic derivatives including dihydroergotamine (DHE) are families of chemical entities that have many different pharmacological effects. This diversity results from their interaction with multiple receptors, their variable receptor affinity and intrinsic activity, and their variable organ-specific receptor access. DHE exhibits alphaadrenergic antagonist activity with only low arterial vasoconstriction potential. The vasoconstrictor activities of these compounds have long been believed to be the basis of their clinical effects, but recent evidence suggests that its antimigraine action may result in part from their inhibitory effects on neurogenic inflammation and neuronal transmission and in part from vasodilatation inhibition and/or correction (Hoskin et al., 1996; Panconesi & Sicuteri, 1997; Goadsby, 2000) . The long duration of action of DHE appears to result from its major active metabolite 8 0 -OH-DHE which is present, in case of oral repeated administration, at a concentration five to seven times greater than DHE (C max for DHE 5 -35 nm) and its long half-life (10 -13 h) has been proposed to account for the low rate of headache recurrence observed with DHE (Silberstein, 1997) . The antimigraine drug DHE produces selective vasoconstriction in the external carotid artery (Villalon et al., 1999) . Both sumatriptan and DHE are effective in aborting migraine headaches. However, headache recurrence is two and a half time as likely with sumatriptan as with DHE (Winner et al., 1996) .
To elucidate if 5-HT 2 Rs could be involved in the long-term antimigraine prophylactic action of DHE via its metabolite 8 0 -OH-DHE, we determined their pharmacological profiles toward the human 5-HT 2B and 5-HT 2C Rs. We, then, investigated the effects of chronic exposure to these compounds of cells expressing these receptors. We observed different responses to these compounds, the 5-HT 2B Rs being the most responsive and chronically affected by 8 0 -OH-DHE. 
Methods

Materials
Cell cultures
The previously described transfection method to obtain clones of human 5-HT 2B R-expressing LMTK À fibroblasts (Choi et al., 1994) was applied to obtain clones of human 5-HT 2C Rexpressing fibroblasts. Stable clonal cell lines were grown in Dulbecco's modified Eagle's medium (DMEM) containing 10% 5-HT-depleted foetal calf serum (FCS). Single clones expressing similar amount of receptors were selected and used at similar passages.
Radioligand binding experiments
They were performed on crude membranes of transfected cells prepared using [
I25 I]DOI as radiolabelled compound as previously detailed (Loric et al., 1995; Kellermann et al., 1996) . Briefly, to prepare crude membranes for binding assays, cells were washed twice with cold phosphate buffer saline (PBS), then harvested with a rubber policeman in PBS containing 1 mg ml À1 pepstatin, 1 mg ml À1 antipain, 15 mg ml
À1
benzamidine, and 0.1 mm phenylmethylsulphonyl fluoride. After centrifugation, the resulting pellet was frozen at À701C before homogenisation. Frozen cell pellets were thawed at 371C, resuspended with 10 ml of cold 4 mm EDTA, 1 mm EGTA, 0.1 mm phenylmethylsulphonyl fluoride, 10 mm imidazole buffer, pH 7.30, and centrifuged for 10 min at 5000 Â g. The supernatant obtained from this centrifugation was collected, poured onto a 20% sucrose cushion, and then centrifuged for 90 min at 100,000 Â g. The membrane-containing pellet was resuspended in 75 mm KCl, 5 mm MgCl 2 , 1 mm EGTA, 10 mm imidazole buffer, pH 7.30, for use in binding assays. Protein contents were determined using the bicinchoninic acid protein assay (Pierce, Chichester, U.K.). Binding experiments were carried out at room temperature under shaking in a total volume of 1 ml. The specific binding was defined as the binding that was inhibited by 1 mm levels of ritanserin. Assays were initiated by the addition of 50 ml of 50 mm Tris buffer, pH 7.40, containing 25 nm of radiolabelled ligand and appropriate competing ligands (12 different concentrations of compounds DHE, and 8 0 -OH-DHE) to 50 ml of membranes (20 mg of protein). A 30-min incubation period was followed by the addition of 5 ml of ice-cold 10 mm Tris buffer, pH 7.40. Samples were filtered on polyethyleneimine-treated filters and the radioactivity retained by the filters was determined as previously described (Bruns et al., 1983) . This was repeated independently at least three times.
Determination of intracellular cGMP levels
Cells were washed twice in fresh serum-free medium and incubated for various times at 371C with 100 mm isobutylmethylxanthine and test agents. The reaction was stopped by aspiration of the medium followed by addition of 500 ml icecold 95% ethanol/5% formic acid (1 : 1, v/v). After 1 h at 41C, the ethanolic phase was collected and lyophilised. cGMP was 278
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Dihydroergotamine and 5-HT 2 receptors quantified using an iodinated radioimmunoassay kit (cGMP RIA kit RPA 525, Amersham Pharmacia Biotech, Buckinghamshire, U.K.).
Desensitisation, receptor expression
Transfected cells maintained in DMEM containing 10% 5-HT-depleted FCS and 300 mg ml À1 of hygromycin were seeded in 12-or 24-well at a density of 4 Â 10 4 cells cm
À2
. After 24-h, cells were rinsed in HBSS and incubated 24-h in serum-free medium [DMEM/F-12 (1 : 1) with 5 mg ml À1 insulin, 5 mg ml À1 transferrin, 30 nm selenium, 20 nm progesterone, and 100 mm putrescine]. Stably transfected mouse fibroblasts LMTK were exposed to saturating concentration of DHE (1 mm 
Desensitisation, receptor transduction
Transfected cells were rinsed, incubated 24-h in serum-free medium and exposed to a saturating concentration of DHE (1 mm) (or 8 0 -OH-DHE) for various time (1, 2, 5, 10, 20 and 40 h) and the cGMP levels were determined as described before (Manivet et al., 2000) using an iodinated radioenzymatic assay kit (cGMP RIA kit RPA 525, Amersham Pharmacia Biotech). Three to four independent experiments were performed with each measure determined in triplicate.
Similarly treated cells maintained in DMEM containing 10% 5-HT-depleted FCS and exposed to saturating concentration of DHE (1 mm) (or 8 0 -OH-DHE) for various time (1, 2, 5, 10, 20 and 40 h) were used to determine the IP 3 levels as described before (Loric et al., 1995) using an iodinated radio receptor assay kit (IP 3 kit TRK 1000, Amersham). Three to four independent experiments were performed, each measure determined in triplicate.
Data analysis
Binding data were analysed using the iterative nonlinear fitting software Graphpad-Prism 2.0. This allowed to determine IC 50 values and to calculate inhibition constants (K i ) according to the Cheng -Prusoff equation. Data points were F-tested to fit a single-or two-site model with or without an additional parameter regarded as nonspecific binding.
Results
We have generated clones of stably transfected LMTK cells expressing human 5-HT 2B or 5-HT 2C Rs to assess their respective affinity for DHE and 8 0 -OH-DHE by competition towards [ ]DOI on crude membrane extracts as previously described (Loric et al., 1995; Kellermann et al., 1996) . Affinities for standard 5-HT 2 R agonists (Table 1) were found similar to previously published values (Cussac et al., 2002) , indicating that they are not affected by expression levels of these receptors in the cell lines at passages used in this study. DHE and 8 0 -OH-DHE interacted with these receptors at high affinity. However, iterative curve fitting suggested the presence of more than one site for 8 0 -OH-DHE (Hill number of 1.79, Po0.01, Table 2 ) at 5-HT 2B Rs that displayed the highest affinity (K i ¼ 8.8570.13) (Figure 1 ).
Intracellular levels of IP 3 have been reported to be increased in cells expressing 5-HT 2B or 5-HT 2C Rs in response to agonist stimulation (Loric et al., 1995; Lucaites et al., 1996) . As previously shown for 5-HT (Manivet et al., 2000) , cGMP levels were elevated upon stimulation by DHE or 8 0 -OH-DHE of LMTK À cells expressing 5-HT 2B or 5-HT 2C Rs, thus, both compounds behaved as agonists. The EC 50 values observed corresponded to the high-affinity sites previously identified, the pEC 50 of 8 0 -OH-DHE being 8.3270.09 at 5-HT 2B and 7.8370.06 at 5-HT 2C Rs for cGMP. In addition, 8 0 -OH-DHE acts as a partial agonist towards 5-HT 2C Rs (Figure 2) .
To assess the effect of long-term exposure to these compounds, stably transfected LMTK À cells expressing 5-HT 2B or 5-HT 2C Rs were exposed to saturating concentration (1 mm) of DHE or 8 0 -OH-DHE for various time (0, 1, 2, 5, 10, 20 and 40 h) and the number of sites (B max ) was measured by competition against [ 125 I]DOI binding. This pharmacological evaluation of receptor expression indicated that 5-HT 2B and 5-HT 2C Rs responded differently to these two compounds, the 5-HT 2B Rs being more sensitive to chronic stimulation by 8 0 -OH-DHE than 5-HT 2C Rs. After 2 h exposure to 8 0 -OH-DHE, 60% of the initial stimulated level of 5-HT 2C R was still detected, whereas only 43% of the 5-HT 2B R initial level remained. Moreover, after 40 h of exposure to 8 0 -OH-DHE, 5-HT 2C R expression level returned to the initial value but this level was only 86% for 5-HT 2B Rs (Figure 3) . The number of sites of 5-HT 2B R and 5-HT 2C R was much less affected by chronic exposure to DHE and returned to initial values within 10 -15 h. At 20 h, the number of sites of 5-HT 2B R and 5-HT 2C R was variably affected by exposure to other 5-HT 2 R agonists (Table 3) . 
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Stably transfected LMTK À cells expressing 5-HT 2B or 5-HT 2C Rs were exposed to saturating concentration (1 mm) of DHE or 8 0 -OH-DHE for various time (0, 1, 2, 5, 10, 20 and 40 h) and the cGMP levels were assessed by radioimmunoassay. This experiment indicated that coupling of 5-HT 2B and 5-HT 2C Rs to cGMP also behaved differently in response to these two compounds. The 5-HT 2B R stimulation of cGMP was more reduced after chronic stimulation by 8 0 -OH-DHE than 5-HT 2C Rs as previously observed for B max (Figures 3 and 4) . The lowest cGMP level was recorded after 2 h exposure of 5-HT 2B Rs-expressing cells to 8 0 -OH-DHE, in which only 14% of the initial stimulated level of cGMP remained, while 50% of the initial level of stimulated cGMP was detected in 5-HT 2C Rsexpressing cells. After 40 h of exposure to 8 0 -OH-DHE, the cGMP level returned to the initial value for 5-HT 2C Rs but this level was only 75% for 5-HT 2B Rs (Figure 4) . The cGMP coupling of 5-HT 2B and 5-HT 2C Rs was much less affected by chronic exposure to DHE than to 8 0 -OH-DHE, as initial desensitisation was subsequently completely reversed.
Since IP 3 is the classical transduction pathways to both receptors, we also evaluated the coupling to IP 3 production by stably transfected LMTK À cells expressing 5-HT 2B or 5-HT 2C Rs after exposure to saturating concentration (1 mm) of DHE or 8 0 -OH-DHE for various time (0, 1, 2, 5, 10, 20 and 40 h). The IP 3 coupling of 5-HT 2B and 5-HT 2C Rs was indeed found but with different responses to chronic exposure to these two compounds. The 5-HT 2B Rs stimulation of IP 3 levels was also more affected after chronic stimulation by 8 0 -OH-DHE than 5-HT 2C as previously observed for B max and cGMP. The lowest IP 3 stimulation level was recorded after 5 h exposure of 5-HT 2B R-expressing cells to 8 0 -OH-DHE, in which only 30% of the initial levels of IP 3 remained. In 5-HT 2C R-expressing cells, the lowest IP 3 level was 35% of the initial level and was detected after 2 h exposure to 8 0 -OH-DHE. Strikingly, after 40 h, 5-HT 2C R IP 3 -coupling reached 86% of the initial value but this level remained stable at 50% of the initial values for 5-HT 2B Rs ( Figure 5 ). As for cGMP, the IP 3 coupling of 5-HT 2B and 5-HT 2C Rs was much less affected by chronic exposure to DHE than to 8 0 -OH-DHE, as initial desensitisation was subsequently completely reversed. These results indicate that chronic exposure to DHE leads to permanent impairment of the coupling efficiency of 5-HT 2B Rs through its metabolite 8 0 -OH-DHE.
Discussion
To our knowledge, this is the first functional characterisation of DHE and its major metabolite 8 0 -OH-DHE at the 5-HT 2B and 5-HT 2C Rs described to date. Unfortunately, it is not possible to study receptors in native tissues due to the lack of complete segregation of receptors in discrete areas. The use of recombinant expression systems is therefore a useful approach, and also allows the study of human receptors. The two human receptor subtypes, 5-HT 2B and 5-HT 2C Rs were transfected into LMTK À cells thus ensuring they were studied in an identical background. Parental nontransfected cells when examined under an identical experimental paradigm did not exhibit a concentration-dependent rise in second messengers in response to agonists. The above cell lines were therefore chosen as they express a single receptor of interest at relatively low and close to physiological levels and they were used at nearly similar passages to ensure stable expression levels. DHE had previously been reported to exhibit alpha-adrenergic antagonist and 5-HT 1A , 5-HT 1B , 5-HT 1D , and 5-HT 1F R agonist activity (EC 50 around 1.5, 10, 0.5, and 10 nm, respectively) (Buzzi & Moskowitz, 1991; Boess & Martin, 1994; Silberstein, 1997) . No data about 8 0 -OH-DHE have been published. Observed values for 5-HT 2B R are within the same range suggesting that its stimulation is physiologically likely.
External carotid vasoconstrictor responses to DHE are mediated by 5-HT 1B/1D Rs as well as alpha2-adrenoceptors (Villalon et al., 1999) . The moderate vasodilator response of cranial arteriovenous anastomoses to the ergot derivatives seems to be mediated, at least in part, by 5-HT 1B/1D Rs (De Vries et al., 1998) . DHE does not contract isolated rat aorta rings, but insurmountably blocks contractions in response to 5-HT. As this response has been reported to be potently (pK B 8.1) and competitively antagonised by the selective 5-HT 2A R antagonist, ketanserin (Kalkman & Schneider, 1996) , it is thought to be mediated by the HT 2A R. Thus, DHE appears to be an antagonist of the HT 2A R. The 5-HT 2A , 5-HT 2B , and 5-HT 2C Rs share a high degree of sequence homology and have very similar pharmacological profiles (Rothman et al., 2000) . DHE inhibits [ 3 H]-mesulergine binding to HT 2C Rs in piglet choroid plexus with a pK D of 7.1, rather less than that of 5-HT (pK D 8.1) and is a full agonist (pEC 50 7.6) but with potencies similar to that of 5-HT (pEC 50 7.7) (Brown et al., 1991) . Concerning the 5-HT 2B R, there was only indirect information originating from pharmacological studies of endotheliummediated relaxation of pig pulmonary or cerebral arteries, which show a pharmacological profile very close to that observed on transfected cells expressing the 5-HT 2B R (Glusa & Roos, 1996; Schmuck et al., 1996; Glusa & Pertz, 2000) . The 5-HT 2B and 5-HT 2C R-expressing cell lines used in the present study display very similar affinities for previously characterised agonists (Table 1) (Cussac et al., 2002) . However, the 8 0 -OH-DHE presents complex interactions toward the 5-HT 2B Rs with a Hill number of 1.79, suggesting multiple interaction sites (Table 2) , the highest affinity site for 5-HT 2B Rs being the most efficient. Our results clearly show that DHE and for the first time 8 0 -OH-DHE act as agonists vs both 5-HT 2B and 5-HT 2C Rs.
Although it is also generally believed that the cellular signal transduction mechanisms activated by the 5-HT 2 Rs are indistinguishable, recent data suggest also significant differences in their signalling cascades. 5-HT-stimulated IP 3 production has been previously observed at the 5-HT 2A , 5-HT 2B , and 5-HT 2C Rs (Loric et al., 1995; Briddon et al., 1998) . In response to 5-HT stimulation, 5-HT 2A R-mediated cGMP generation was reported together with calcium (Ca 2 þ ) mobilisation in C6 glioma cells through NO-dependent pathway (Kagaya et al., 1995; Miyoshi et al., 2001 ). The 5-HT 2C Rs expressed in the choroid plexus trigger phosphoinositide turnover and also the formation of cGMP formation in a calcium-sensitive manner (Kaufman et al., 1995) . Concerning the 5-HT 2B R, the pharmacological study of endothelialmediated relaxation of pig pulmonary arteries (Glusa & Roos, 1996; Glusa & Pertz, 2000) showed that DHE, as well as 5-HT and alpha-methyl-5-HT, elicited a reversible endotheliumdependent relaxation of precontracted arterial ring segments, associated with an increase in intracellular cGMP production through direct activation of NO synthase (Manivet et al., 2000) . The present results clearly identify DHE and 8 0 -OH-DHE as agonist for both IP 3 and cGMP second messengers at 5-HT 2B and 5-HT 2C Rs.
Knowing that DHE is generally prescribed for long-term use, we investigated the effect of chronic treatments of cells expressing 5-HT 2B or 5-HT 2C Rs exposed to saturating concentrations (1 mm) of these compounds to ensure their complete desensitisation. Desensitisation is an adaptive mechanism in biological systems thought to facilitate responsiveness of the cell to successive multiple extracellular stimuli over time. The receptor, first uncoupled from the G protein is then sequestered in an intracellular compartment. This step is now viewed as a mechanism that allows dephosphorylation by specific phosphatases and resensitisation of the receptor. Degradation of the protein and reduction of the steady-state mRNA (mostly due to decreased stability of the mRNA) are the concomitant mechanisms leading to the decrease of receptor number (downregulation) (Chuang et al., 1996) . In vivo, when the stimulation is chronically persistent, the receptor transcription is downregulated, but due to the use of a strong promoter containing expression vectors this step cannot be observed in transfected cells. To date, little is known about 5-HT 2B Rs desensitisation. The human 5-HT 2A and 5-HT 2C Rs have been both reported to exhibit receptor uncoupling at the level of IP 3 , with the 5-HT 2C R being more sensitive than the 5-HT 2A R (Briddon et al., 1998) . More recently, the desensitisation characteristics of recombinant human 5-HT 2A , 5-HT 2B , and 5-HT 2C Rs stably expressed in CHO-K1 cells, investigated by calcium fluorimetry showed that 5-HT 2B Rs exhibited the most dramatic degree of desensitisation to 5-HT, with a rapid time course. The partial agonists metachlorophenylpiperazine (mCPP) and DOI also elicited desensitisation, generally in line with their relative efficacies at each receptor (Berg et al., 2001; Porter et al., 2001) . For the first time, we have studied long-term effects of DHE exposure and found that 5-HT 2B Rs exhibit the most dramatic degree of desensitisation in respect to both IP 3 and cGMP coupling by its metabolite 8 0 -OH-DHE, which is more effective and permanent. Further experiments are necessary to elucidate the molecular mechanism involved in this phenomenon.
Both neuronal and vascular mechanisms have been proposed on the basis of actions of 5-HT in migraine. Blockade of neural transmission and the neurogenic inflammatory response provides a mechanism by which sumatriptan and ergot alkaloids alleviate vascular headaches (Moskowitz, 1992) . The vasodilatory theory of migraine suggests that extracranial arterial dilation during an attack is related to migraine pain, whereas in the neurogenic dural inflammation theory of migraine, inflammation of the dural membrane surrounding the brain is due to release of neuropeptides from primary sensory nerve terminals. Substance P, calcitonin gene-related peptide and NO all play a role in the dural inflammatory cascade. Pretreatment with the antimigraine drugs DHE and sumatriptan markedly attenuates plasma protein extravasation induced by electrical trigeminal ganglion stimulation (Buzzi & Moskowitz, 1991; Hoskin et al., 1996) . Pharmacological agents such as mCPP and NO donors have also been used to induce dural extravasation in animals. NO is suspected to play a key role in migraine since NO donors cause a dose-dependent headache with several migrainous characteristics. A cause of migraine could be increased amounts and/or affinity of an enzyme in the NO-triggered cascade of reactions (Olesen et al., 1994) . NO, which may be released from blood vessels, perivascular nerve endings or from brain tissue, is an important molecular trigger mechanism in spontaneous headache pain (Thomsen & Olesen, 2001) . It has been shown that 5-HT 2B Rs stimulate the NO production in cell lines (Manivet et al., 2000) and relaxation of the pig cerebral artery (Schmuck et al., 1996) . Thus, 5-HT 2B Rs located on endothelial cells of meningeal blood vessels have been proposed to trigger migraine headache through the formation of NO. Recent data are consistent with this hypothesis, since activation by mCPP of peripheral 5-HT 2B Rs initiates dural plasma protein extravasation via NO (Johnson et al., 2003) .
In conclusion, the DHE long half-life may account for the low rate of headache recurrence at least partially through permanent inhibition of vascular 5-HT 2B -dependent second messengers (NO) via its major active metabolite 8 0 -OH-DHE. Whether the antimigraine action of DHE involves a combination of acute agonist action at 5-HT 1B/1D Rs, a long-lasting uncoupling of 5-HT 2B Rs via 8 0 -OH-DHE and an insurmountable antagonist action at 5-HT 2A Rs remains to be established on cerebral vasculature.
